The overall 5-year relative survival rate for bladder cancer depends heavily on how far the disease has spread at diagnosis. When caught early and still confined to the bladder, the 5-year survival rate is about 71 to 73%. That number drops significantly with more advanced disease: roughly 40% when cancer has reached nearby lymph nodes or organs, and under 10% when it has spread to distant parts of the body.
These are population-level averages drawn from the National Cancer Institute’s SEER database, based on data from 2016 to 2022. An individual’s outlook depends on the specific type of bladder cancer, how deeply it has grown into the bladder wall, and how the cancer responds to treatment.
Survival Rates by Stage at Diagnosis
Bladder cancer staging uses three broad categories in national survival databases: localized, regional, and distant. Each carries a very different prognosis.
- Localized (cancer confined to the bladder): About 34% of bladder cancers are caught at this stage. The 5-year relative survival rate is 73%.
- Regional (spread to nearby lymph nodes or surrounding tissue): Around 7% of cases are diagnosed here. The 5-year survival rate drops to roughly 40%.
- Distant (cancer has metastasized to other parts of the body): About 6% of diagnoses fall in this category, with a 5-year survival rate near 9%.
A “relative” survival rate compares people with bladder cancer to the general population of the same age. So a 73% relative survival rate means that people with localized bladder cancer are 73% as likely to be alive five years later as people without the disease. It accounts for the fact that older adults, who make up most bladder cancer patients, face other health risks as well.
You’ll notice these three groups only account for about 47% of cases. The remaining cases are either unstaged at diagnosis or classified differently, which is why you won’t find a single “overall” number that neatly covers everyone.
Why Early-Stage Bladder Cancer Still Needs Close Monitoring
Most bladder cancers are non-muscle-invasive at diagnosis, meaning they haven’t grown deep into the bladder wall. This is generally good news for survival, but these cancers have an unusually high tendency to come back. The 3-year recurrence risk after a first tumor is about 31%. After a second recurrence, the risk of yet another climbs to 45%, and after a third it reaches 54%.
Recurrence doesn’t always mean the cancer has gotten worse. Many recurrences are superficial tumors that can be removed again. But a subset of non-muscle-invasive cancers do progress into the muscle wall over time, which shifts the prognosis into a more serious category. This is why bladder cancer patients typically undergo regular cystoscopies (a scope exam of the bladder) for years after their initial treatment. The surveillance schedule can feel burdensome, but catching a recurrence early keeps the cancer in the more treatable, higher-survival category.
Muscle-Invasive Bladder Cancer: Surgery vs. Bladder-Sparing Treatment
When bladder cancer grows into the muscle layer of the bladder wall, treatment decisions become more consequential. The two main approaches are radical cystectomy (complete removal of the bladder) and trimodality therapy, which combines aggressive tumor removal through the urethra with chemotherapy and radiation to preserve the bladder.
A large multi-institutional study published in The Lancet Oncology compared these two approaches head-to-head and found strikingly similar outcomes. Five-year cancer-specific survival was 81 to 83% for bladder removal and 84 to 85% for bladder-sparing treatment. Five-year disease-free survival was essentially identical at 73 to 76% for both groups. Overall survival actually slightly favored the bladder-sparing approach, with 5-year rates of 73 to 77% compared to 66 to 72% for surgery.
These numbers are encouraging for patients who want to keep their bladder, though not everyone is a candidate for the bladder-sparing approach. Tumor size, location, and how completely the initial tumor can be removed all factor into which option your care team recommends.
What Affects Your Individual Outlook
Stage at diagnosis is the single biggest factor in bladder cancer survival, but it isn’t the only one. Several other variables influence how the disease behaves.
Tumor grade matters significantly. Low-grade bladder cancers grow slowly and rarely become life-threatening. High-grade tumors are more aggressive, more likely to invade the muscle wall, and more likely to spread. Most bladder cancer deaths come from high-grade disease.
Lymph node involvement is another critical marker. When cancer has reached the lymph nodes near the bladder, the 5-year survival rate falls from over 70% to around 39 to 42%. This is one reason that surgical treatment for muscle-invasive cancer typically includes removing pelvic lymph nodes: both for treatment and to accurately assess how far the cancer has traveled.
Age and overall health also play a role. Bladder cancer is most commonly diagnosed in people over 65, and older patients may not tolerate aggressive treatments as well, which can affect outcomes. The type of bladder cancer matters too. The most common form, urothelial carcinoma, responds well to current treatments. Rarer variants like squamous cell or small cell bladder cancer tend to be more aggressive and carry lower survival rates.
How Metastatic Bladder Cancer Is Changing
The 9% five-year survival rate for distant bladder cancer reflects a historical reality that is slowly shifting. For decades, platinum-based chemotherapy was the only systemic option, and most patients saw their cancer return within a year. Immunotherapy drugs that help the immune system recognize and attack cancer cells have become part of standard treatment in recent years, both as a follow-up after chemotherapy and for patients who can’t tolerate chemo.
Newer drug combinations, including antibody-drug conjugates that deliver chemotherapy directly to cancer cells, have also shown meaningful improvements in how long patients with advanced disease survive. While the SEER statistics haven’t yet caught up to these newer treatments (the data reflects patients diagnosed from 2016 to 2022, many of whom were treated before these options were widely available), oncologists are seeing longer responses in clinical practice. The 5-year numbers for metastatic disease will likely improve as more recent treatment data enters the national databases.